Mājas>Klīniskā pētniecība>Klīniskie izmēģinājumi>SPECT

How to use the speech recognition tool?

NCT03079141

SPECT

Half-dose photodynamic therapy versus eplerenone treatment in chronic central
serous chorioretinopathy.

Type: Interventional



Status of the trial: Active, Not recruiting

Orphan Drug Recognition: NA

Inclusion

  • Opening Date: 2017-02-20
  • Closing Date: 2019-02-20

Criteria

Inclusion: chronic central serous chorioretinopathy, no steroid use, duration < 18 months

Exclusion: steroid use, duration > 18 months, signs of other diagnosis, previous treatment

More information

Children: Yes

Adults: Yes

Funder Type: other

HCP: Other investigators


Within ERN-EYE members

Principal investigators




Other investigators

Workgroups

  • Retinal Rare Eye Diseases (WG1)

Subscribe to our mailing list

* indicates required

This ERN is supported by: